Albumin human



Albumin human is a purified form of human serum albumin used to replace lost albumin in patients with hypoalbuminemia, to treat hypovolemia and ascites, and as a part of some diagnostic imaging kits.

Brand Names
Albuked, Albuminex, Alburex, Alburx, Albutein, Flexbumin, Hizentra, Human Albumin Grifols, Kedbumin, Octalbin, Plasbumin, Plasmanate
Generic Name
Albumin human
DrugBank Accession Number

Human serum albumin is the primary protein present in human blood plasma. The main function of albumin is to maintain the oncotic pressure of blood 2. It binds to water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates). Albumin represents approximately 50% of the total protein content in healthy humans 5.

Human albumin is a small globular protein (molecular weight: 66.5 kDa), consisting of a single chain of 585 amino acids organized in three repeated homolog domains (sites I, II, and III). Each domain comprises two separate sub-domains (A and B) 5.

There are various preparations of albumin that are well established and widely available in the clinical setting 9, 10, 6.

Also known as Albuminex 5% or 25%, one brand of human serum albumin is prepared from the pooled plasma of US donors in FDA-licensed facilities in the US 12. This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 6.

Biologic Classification
Protein Based Therapies
Blood factors
Protein Structure
Protein Chemical Formula
Protein Average Weight
66472.2 Da
> Human Serum Albumin Sequence
Download FASTA Format
  • Albumin (human)
  • Albumin human
  • Albumin, blood
  • Albumin, human
  • Albumin, human-kjda
  • Human albumin
  • Human serum albumin
  • Serum albumin



Albuminex solution is indicated for adults and children for hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome and cardipulmonary bypass 12.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofAcute liver failure•••••••••••••••••••••
Management ofAcute nephrosis•••••••••••••••••••••
Management ofBurns•••••••••••••••••••••
Management ofHemolytic disease of the newborn•••••••••••••••••••••
Treatment ofHypoalbuminemia•••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Serum albumin is a soluble, monomeric protein essential for maintaining and regulating the colloidal osmotic pressure of blood. It is utilized to increase the circulating plasma volume, which reduces hemoconcentration and blood viscosity. Albumin is also used as a transport protein that binds naturally occurring, therapeutic and toxic materials and drugs in the circulation 12.

Human albumin makes up over 50% the total protein in the plasma and represents about 10% of protein synthesis activity by the liver. Human Albumin 25% has a corresponding hyper-oncotic effect 13.

Mechanism of action

The main function of albumin results from its contribution to plasma colloid oncotic pressure and transport function 13.

Albumin stabilizes circulating blood volume and carries hormones, enzymes, medicines, and toxins. Other physiological functions include antioxidant properties, free radical scavenging, in addition to maintenance capillary membrane integrity 13.

Exogenously administered albumin increases the oncotic pressure of the intravascular system, moving fluids from the interstitial space, thereby decreasing edema and increasing the circulating blood volume. The increase in volume reduces the concentration and viscosity of blood in patients with decreased circulating blood volume while maintaining cardiac output in shock. In dehydrated patients, negligible effects exist on circulating blood volume. In addition to the above albumin replaces protein in patients with hypoproteinemia until the cause of the deficiency can be determined 8.

This drug has thousands of endogenous and exogenous targets. Human albumin also binds and carries a plethora of hydrophobic molecules, such as endogenous (i.e., cholesterol, fatty acids, bilirubin, thyroxine) or exogenous substances (for example, drugs and toxins), transition metal ions, as well as gas (nitric oxide NO), with resulting implications for their solubilisation, transport, metabolism, and detoxification 5.

UNitric oxide

Not Available

Volume of distribution

Albumin is distributed throughout the extracellular space and more than 60% of the body albumin pool is located in the extravascular fluid space 13.

In healthy adults, less than 10% of infused albumin leaves the intravascular compartment during the first 2 hours following infusion of albumin. There is considerable individual variation in the effect of albumin on plasma volume, however 12, 13.

In some patients, the plasma volume can remain elevated for several hours. In critically ill patients, however, albumin can leak out of the vascular space in substantial amounts at an unpredictable rate that is difficult to predict 13.

Protein binding

Not Available

Not Available
Route of elimination

Not Available


Not Available


Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

In general, human albumin solutions are well-tolerated and no specific, clinically relevant alterations in organ function or coagulopathy have been substantiated 12.

The most common adverse reactions are rigors, hypotension, tachycardia with increased heart rate, fever, chills, nausea, vomiting, dyspnea and/or bronchospasm, skin rash/pruritus. Stop the infusion immediately if anaphylaxis, with or without shock is observed 12.

Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the volume status of the patient. When clinical signs of cardiovascular overload occur (headache, dyspnea, jugular venous distention, increased blood pressure), the infusion must be slowed or stopped immediately 13.

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
No interactions found.
Food Interactions
No interactions found.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AlbukedSolution5 g/20mLIntravenousKedrion Biopharma, Inc.1942-10-212017-04-29US flag
AlbukedSolution5 g/20mLIntravenousKedrion Biopharma, Inc.1942-10-21Not applicableUS flag
AlbukedSolution10 g/50mLIntravenousKedrion Biopharma, Inc.1981-07-282017-04-29US flag
AlbukedSolution.05 g/1mLIntravenousKedrion Biopharma, Inc.1976-08-262018-01-08US flag
AlbukedSolution10 g/50mLIntravenousKedrion Biopharma, Inc.1981-07-28Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Albumin Human DiluentAlbumin human (.3 mg / mL) + Sodium chloride (9 mg / mL)LiquidSubcutaneousOmega Laboratories Ltd1987-12-31Not applicableCanada flag
MacrotecAlbumin human (10 mg/1) + Albumin Aggregated (1.5 mg/1)Injection, powder, lyophilized, for suspensionIntravenousBracco Diagnostics, Inc1974-05-082008-04-20US flag
Sterile Diluent for Allergenic ExtractAlbumin human (0.0003 mL/1mL) + Phenol (0.004 mL/1mL)Injection, solutionIntradermal; SubcutaneousAntigen Laboratories, Inc.1974-03-23Not applicableUS flag
Venomil Honey Bee Venom (12mcg)Albumin human (1.8 mL / vial) + Apis mellifera venom (12 mcg / vial)Kit; Liquid; Powder, for solutionIntradermalHollister Stier Laboratories Llc1998-09-152005-09-02Canada flag
Venomil Wasp Venom Protein (12mcg)Albumin human (1.8 mL / vial) + Vespula vulgaris venom protein (12 mcg / vial)Kit; Powder, for solutionIntradermalHollister Stier Laboratories Llc1998-09-152005-09-02Canada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
CEALB ALBUMIN %20 100 ML 1 ADET SISEAlbumin human (20 %)SolutionIntravenousCENTURION PHARMA İLAÇ SAN. VE TİC. LTD. ŞTİ.2016-11-29Not applicableTurkey flag
CEALB ALBUMIN %20 50 ML 10 GRAlbumin human (20 %)SolutionIntravenousCENTURION PHARMA İLAÇ SAN. VE TİC. LTD. ŞTİ.2015-09-29Not applicableTurkey flag


ATC Codes
B05AA01 — Albumin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Not Available
Organic Compounds
Super Class
Organic Acids
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Alternative Parents
Not Available
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number


Synthesis Reference

Robert A. Tenold, "Preparing essentially monomeric normal human serum albumin." U.S. Patent USRE0362590, issued July, 1976. Rene Fickat, Simon Benita, Francis Puisieux, "Preparation of biodegradable microcapsules based on serum albumin." U.S. Patent US4666641, issued June, 1958.

General References
  1. Zunszain PA, Ghuman J, Komatsu T, Tsuchida E, Curry S: Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol. 2003 Jul 7;3:6. Epub 2003 Jul 7. [Article]
  2. Moman RN, Bhimji SS: Albumin . [Article]
  3. Neumann E, Frei E, Funk D, Becker MD, Schrenk HH, Muller-Ladner U, Fiehn C: Native albumin for targeted drug delivery. Expert Opin Drug Deliv. 2010 Aug;7(8):915-25. doi: 10.1517/17425247.2010.498474. [Article]
  4. Schussler GC: The thyroxine-binding proteins. Thyroid. 2000 Feb;10(2):141-9. doi: 10.1089/thy.2000.10.141. [Article]
  5. Caraceni P, Tufoni M, Bonavita ME: Clinical use of albumin. Blood Transfus. 2013 Sep;11 Suppl 4:s18-25. doi: 10.2450/2013.005s. [Article]
  6. BLA APPROVAL [Link]
  7. ALBUMIN (HUMAN)- albumin human solution DailyMed [Link]
  8. PDR-Human Albumin [Link]
  9. Alburx [Link]
  10. Human Albumin [Link]
  11. Plasbumin [Link]
  12. Albuminex package insert [File]
  13. Albuminex 25 package insert [File]
  14. CSL Bhering Prescribing Information [File]
PubChem Substance
RxList Drug Page
FDA label
Download (265 KB)
Download (122 KB)

Clinical Trials

Clinical Trials


Not Available
  • ALK-Abello Inc.
  • Alpha Therapeutic Corp.
  • Alpine Biologics Inc.
  • American Red Cross
  • Baxter International Inc.
  • CSL Behring LLC
  • Grifols SA
  • Massbiologics
  • Octapharma USA
  • Sanofi-Aventis Inc.
  • Talecris Biotherapeutics
Dosage Forms
Injection, solutionParenteral200 g/L
Injection, solutionParenteral50 g/L
SolutionIntravenous200 mg/100mL
SolutionParenteral200 g/l
SolutionParenteral50 g/l
Injection, solutionIntravenous50 mg/ml
Injection, solutionIntravenous; Parenteral200 MG/ML
Injection, solutionIntravenous; Parenteral50 MG/ML
SolutionIntravenous.05 g/1mL
Injection, solutionIntravenous200 mg/ml
Injection, solution, concentrateIntravenous200 g/L
SolutionIntravenous200 g/1000mL
SolutionIntravenous250 g/1000mL
SolutionIntravenous50 g/1000mL
Injection, solutionParenteral25 G/100ML
SolutionIntravenous10 g
SolutionParenteral10 g
Solution, concentrateIntravenous20 g
SolutionIntravenous25.000 g
Injection, solutionParenteral200 MG/ML
Injection, solution200 G/L
Injection, solution50 G/L
Injection, solution
Injection, solutionIntravenous2.5 G/50ML
InjectionIntravenous20 %
InjectionIntravenous5 %
SolutionIntravenous20 g/100mL
SolutionIntravenous25 g/100mL
SolutionIntravenous25 g / 100 mL
SolutionIntravenous0.05 g/1mL
SolutionParenteral20.000 g
SuspensionIntravenous5 %
SolutionParenteral250 g/l
SolutionParenteral40 g/l
Injection, solutionIntravenous50 g/1000ml
SolutionIntravenous5.000 g
Injection, solutionParenteral20 %
Injection, solutionParenteral25 %
Injection, solutionParenteral5 %
SolutionIntravenous5 %
SolutionParenteral20 %
SolutionIntravenous25 g
SolutionIntravenous25000000 g/L
SolutionParenteral5 %
SolutionIntravenous200 g
SolutionIntravenous12.5 g/250mL
SolutionIntravenous12.5 g/50mL
SolutionIntravenous250 g/L
SolutionIntravenous50 g/l
Injection, solutionIntravenous10 g/50mL
Injection, solutionIntravenous12.5 g/250mL
SolutionIntravenous0.2 g
SolutionIntravenous250 mg
Injection, solutionIntravenous25 %
SolutionIntravenous50 mg
Injection, solutionIntravenous5 %
InjectionIntravenous10.0 g/50ml
InjectionIntravenous12.5 g/50ml
InjectionIntravenous12.5 g/250ml
InjectionIntravenous200 g/1000ml
SolutionIntravenous200 mg
Injection, solutionIntravenous0.2 g/1mL
Injection, solutionIntravenous0.25 g/1mL
LiquidIntradermal; Subcutaneous0.03 %
Injection, solutionIntravenous0.05 g/1mL
SolutionIntravenous0.20 g/1mL
SolutionIntravenous0.25 g/1mL
SolutionIntravenous20.000 g
SolutionIntravenous20 g
Injection, solutionIntravenous20 g/100mL
Injection, solutionIntravenous20 %
Injection, solutionIntravenous25 g/100mL
SolutionParenteral5.000 g
SolutionIntravenous200 mg/ml
SolutionIntravenous0.2 g/ml
SolutionIntravenous20 %
Injection, solutionIntravenous20 %/50ml
SolutionIntravenous drip200 g/L
Injection, solutionIntravenous12.5 g/50mL
SolutionParenteral10.000 g
Injection, powder, lyophilized, for suspensionIntravenous
Injection, powder, lyophilized, for suspensionIntravenous2 mg
Kit2.5 mg
Injection, powder, lyophilized, for solutionIntravenous; Subcutaneous1 mg
Kit500 Mikrogramm
Injection, powder, lyophilized, for suspensionSubcutaneous
Kit0.5 mg
LiquidIntravenous25 %
SolutionIntravenous5.00 g
SolutionIntravenous25 %
Injection, solutionParenteral250 G/L
SolutionIntravenous10 g/50mL
SolutionIntravenous2.5 g/50mL
SolutionIntravenous5 g/20mL
SolutionIntravenous250 mg / mL
InjectionIntravenous5 g/20ml
SolutionIntravenous50 mg / mL
LiquidIntravenous50 mg / mL
Kit2 mg
Injection, solutionIntravenous
Injection, powder, lyophilized, for solutionSubcutaneous0.5 mg
InjectionIntravenous; Subcutaneous1 mg
Injection, solutionIntravenous0.2 g/mL
SolutionIntravenous20.0000 mg
Injection, solutionIntradermal; Subcutaneous
SolutionSubcutaneous0.03 %
Injection, solutionIntravenous; Parenteral20 %
Injection, solutionParenteral20 G/100ML
Injection, solutionParenteral5 G/100ML
SolutionIntravenous200 g/l
SolutionIntravenous1000000 g
Injection, solutionParenteral
Injection, solutionIntravenous
Kit; liquid; powder, for solutionIntradermal
Kit; powder, for solutionIntradermal
InjectionIntravenous20 % w/v
InjectionIntravenous4.5 % w/v
Injection, solutionIntravenous4.5 %
Unit descriptionCostUnit
Buminate 25% iv solution2.22USD ml
Albumin 25% iv solution1.97USD ml
Albutein 25% vial1.32USD ml
Buminate 5% iv solution0.44USD ml
Albutein 5% iv solution0.43USD ml
Albumin (human) 5% iv solution0.3USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5558094No1996-09-242012-02-28US flag
US6723303No2004-04-202021-04-20US flag


Experimental Properties
Not Available


Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Small molecule
Pharmacological action
  1. Caraceni P, Tufoni M, Bonavita ME: Clinical use of albumin. Blood Transfus. 2013 Sep;11 Suppl 4:s18-25. doi: 10.2450/2013.005s. [Article]
  2. Ishima Y, Kragh-Hansen U, Maruyama T, Otagiri M: Albumin as a nitric oxide-traffic protein: characterization, biochemistry and possible future therapeutic applications. Drug Metab Pharmacokinet. 2009;24(4):308-17. [Article]
  3. Lee P, Wu X: Review: modifications of human serum albumin and their binding effect. Curr Pharm Des. 2015;21(14):1862-5. [Article]

Drug created at June 13, 2005 13:24 / Updated at April 15, 2024 03:58